Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Published:2017-11-28 Issue:7 Volume:59 Page:1659-1665
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ruggiu Mathilde¹,Oberkampf Florence¹,Ghez David²,Cony-Makhoul Pascale³,Beckeriche Florence⁴,Cano Isabelle¹,Taksin Anne L.¹,Benbrahim Omar⁵,Ghez Stéphanie¹,Farhat Hassan¹,Rigaudeau Sophie¹,de Gunzburg Noémie¹,Lara Diane¹,Terre Christine⁶,Raggueneau Victoria⁶,Garcia Isabel⁶,Spentchian Marc⁶,De Botton Stéphane²,Rousselot Philippe¹⁷

Affiliation:

1. Hematology Department, Centre Hospitalier de Versailles, Versailles, France;

2. Hematology Department, Institut Gustave Roussy, Villejuif, France;

3. Hematology Department, Centre Hospitalier Annecy Genevois, Pringy, France;

4. Hematology Department, Hôpital Henri Mondor, APHP, Créteil, France;

5. Hematology Department, Hôpital La Source, Orléans, France;

6. Hematology Laboratory, Centre Hospitalier de Versailles, Versailles, France;

7. UMR1173, Université Versailles Saint-Quentin-en-Yvelines, Paris, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology